Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1208 - 1211 | |
| Section | M/S Revues | |
| DOI | https://doi.org/10.1051/medsci/2019250 | |
| Publié en ligne | 6 janvier 2020 | |
Med Sci (Paris) 2019 ; 35: 1208–1212
Caractéristiques des anticorps ayant reçu une dénomination commune internationale, cités dans ce numéro de médecine/sciences1
| Anticorps (DCI*) | Cible(s) | Nom commercial | Firmes |
|---|---|---|---|
| abciximab | GPIIbIIIa/ | Réopro | Centocor / Janssen / |
| CD11b/CD18 | Eli Lilly and Company | ||
| αvβ3 | |||
| adalimumab | TNF-α | Humira | Cambridge Antibody Technology(CAT) / AbbVie |
| adécatumumab | EpCAM | - | Micromet / Merck |
| aducanumab | amyloïde β | - | Neurimmune / Biogen |
| (A-β fibrillaire) | |||
| ado-trastuzumab emtansine (DM1) | HER2/neu | Kadcyla | Genentech (Roche) / Lonza |
| aérubumab | Ps°°°° | Aerucin | Aridis Pharmaceuticals |
| alemtuzumab | CD52 | Lemtrada | Sanofi Genzyme |
| alirocumab | PCSK9++ | Praluent | Sanofi-Aventis |
| anifrolumab | IFNAR1 | - | Medimmune LLC / AstraZeneca |
| atézolizumab | PD-L1 | Tecentriq | Genentech (Roche+) |
| avélumab | PD-L1 | Bavencio | Merck Sharp & Dohme / Pfizer |
| basiliximab | IL-2Rα (CD25) | Simulect | Novartis |
| bavituximab | Phosphatidylsérine | - | Peregrine Pharmaceuticals |
| bélantamab mafodotine. | BCMA (TNFRSF17) | - | GlaxoSmithKline |
| bélimumab | BLyS (BAFF) | Benlysta | GlaxoSmithKline |
| benralizumab | IL-5R | Fasenra | AstraZeneca |
| bévacizumab | VEGF-A | Avastin | Roche |
| bézlotoxumab | entérotoxine B | Zinplava | Merck Sharp & Dohme |
| Clostridium difficile | |||
| bimékizumab | IL-17A/F | - | UCB |
| blésélumab | CD40 | - | Kiowa Kirin Pharmaceuticals |
| blinatumomab | CD3εxCD19 | Blincyto | Micromet / Amgen |
| bococizumab | PCSK9 | - | Pfizer |
| brentuximab védotine | CD30 | Adcetris | Seattle Genetics |
| burosumab | FGF23 | Crysvita | Kyowa Hakko Kirin Pharma |
| cabiralizumab | CSF1-R (CD115) | - | Five Prime Therapeutics/ Bristol-Myers Squibb |
| camrélizumab | PD-1 | - | Jiangsu HengRui Medicine |
| canakinumab | IL-1β | Ilaris | Novartis |
| caplacizumab | vWF | Cablivi | Sanofi |
| catumaxomab | CD3ε x EpCAM | Removab | Fresenius Biotech / Trion Pharma |
| cémiplimab | PD-1 (CD279) | Libtayo | Regeneron / Sanofi |
| cergutuzumab amunaleukin | ACE | - | Roche |
| certolizumab pégol | TNF-α | Cimzia | UCB Pharma |
| cétrélimab | PD-1 (CD279) | - | Janssen |
| cétuximab | EGF-R | Erbitux | Imclone / Merck Serono |
| conatumumab | TRAIL-R2(DR5, APO-2) | - | Amgen / Takeda |
| concizumab | TFPI°°° | - | Novo Nordisk |
| cosfroviximab | Gp surface Ebola virus≠ | ZMapp | Mapp Biopharmaceuticals |
| crénézumab | amyloïde β(A-β fibrillaire) | - | Genentech (Roche) |
| cusatuzumab | CD70 | - | Argenx / Janssen Cilag |
| dacétuzumab | CD40 | - | Seattle Genetics / Genentech |
| daclizumab | CD25 (IL-2Rα) | Zinbryta | Protein Design Labs BioPharma / Biogen / AbbVie |
| dapirolizumab pégol | CD40L (CD154) | - | UCB Pharma |
| daratumumab | CD38 | Darzalex | Janssen |
| dénosumab | RANKL | Prolia / Xgeva | Amgen |
| dépatuxizumab madofotine | EGF-RvIII | - | AbbVie |
| dinutuximab bêta | GD2 | Qarziba | EUSA Pharma / Jazz Pharmaceuticals |
| diridavumab | HA## | - | Janssen |
| drozitumab | TRAIL-R2(DR5, APO-2) | - | Genentech (Roche) |
| dupilumab | IL-4/IL-13Rα | Dupixent | Regeneron / Sanofi |
| durvalumab | PD-L1 | Imfinzi | MedImmune LLC / AstraZeneca |
| éculizumab | C5 | Soliris | Alexion Pharmaceuticals |
| éfalizumab | CD11a | Raptiva | Genentech / Merck Serono |
| éfungumab | Hsp90≠≠ | Mycograb | NeuTec Pharma / Novartis |
| élotuzumab | SLAMF7 | Empliciti | Bristol-Myers Squibb |
| émactuzumab | CSF1-R (CD115) | - | Genentech / Roche |
| émicizumab | facteurs IXa x X | Hemlibra | Chugai (Roche) |
| enfortumab védotin | nectine 4 | - | Seattle Genetics |
| énoblituzumab. | B7-H3 (CD276) | - | MacroGenics |
| eptinézumab | CGRP$$ | - | Alder Biopharmaceuticals |
| érénumab | CGRP | Aimovig | Amgen / Novartis |
| erlizumab | CD18 | - | Genentech (Roche) |
| ertumaxomab | HER2/neu x CD3εx RFcγI/II/III | - | Fresenius Biotech |
| étanercept | TNF-α | Enbrel | Pfizer |
| étigilimab | TIGIT | - | Oncomed / Mereo BioPharma |
| énoblituzumab | B7-H3 (CD276) | - | MacroGenics |
| évolocumab | PCSK9++ | Repatha | Amgen |
| farlétuzumab | Folate receptor 1 | - | Morphotek |
| felvizumab | F§§(protéine de fusion) | - | GlaxoSmithKline |
| flotétuzumab | CD123 x CD3e | - | MacroGenics |
| foravirumab | gp I et gpIII§§§ | - | Crucell / Sanofi Pasteur |
| frémanézumab | CGRP | Ajovy | Teva |
| frésolimumab | TGF-β | - | Genzyme (Sanofi) |
| futuximab | EGFR (Erb1, HER1) | - | Symphogen |
| galcanézumab | CGRP | Emgality | Eli Lilly & Company |
| galiximab | CD80 | Biogen (ex-Biogen Idec) | |
| ganténérumab | amyloïde β(A-β fibrillaire) | - | Roche |
| gédivumab | HA | - | Genentech (Roche) |
| gemtuzumab ozogamicin | CD33 | Mylotarg | Celltech / Wyeth |
| golimumab | TNF-α | Simponi | Janssen |
| grémubamab | PcrV et PsI++++ | - | MedImmune (AstraZeneca) |
| guselkumab | IL-23Rp19 | Tremfya | Janssen |
| ibalizumab | CD4 | Trogarzo | Theratechnologies |
| ibritumomab tiuxetan | CD20 | Zevalin | Spectrum Pharmaceuticals / Acrotech Biopharma |
| idarucizumab | Dabigatran | Praxbind | Boehringer Ingelheim |
| inclacumab | Sélectine P | - | Roche |
| infliximab | TNF-α | Remicade | NYU°° / Janssen |
| inotuzumab ozogamicine | CD22 | Besponsa | Pfizer |
| ipilimumab. | CTLA-4 | Yervoy | Medarex / Bristol-Myers Squibb |
| isatuximab | CD38 | - | Sanofi |
| iscalimab | CD40 | - | Xoma / Novartis |
| ixékizumab | IL-17A | Taltz | Eli Lilly & Company |
| lacnotuzumab | CSF-R (CD115) | - | Novartis |
| lanadélumab | kallicréine | Takhzyro | Takeda / Shire |
| larcaviximab | Gp surface Ebola virus | ZMapp | Mapp Biopharmaceuticals |
| lenvervimab | Ag HBs§ | - | GC Pharma |
| léronlimab | CCR5 | - | CytoDyn |
| lexatumumab | TRAIL-R2(DR5, APO-2) | - | Human Genome Sciences / Cambridge Antibody Technology |
| ligélizumab | IgE | - | Novartis |
| lirilumab | KIR2DL1/L2/L3- | - | Innate Pharma / Bristol-Myers Squibb |
| loncastuximab tésirine | CD19 | - | ADC Therapeutics |
| lucatumumab | CD40 | - | Chiron / Xoma / Novartis |
| lulizumab pégol | CD28 | - | Bristol-Myers Squibb |
| lumiliximab | CD23 (RFcεII) | - | Biogen Idec |
| mapatumumab | TRAIL-R1 (DR4) | - | Human Genome Sciences (GlaxoSmith Kline)/ Cambridge Antibody Technology (AstraZeneca) |
| magrolimab | CD47 | - | Forty Seven Inc. |
| mirvétuximab soravtansine | FOLR1 | - | ImmunoGen |
| mitazalimab | CD40 | - | Alligator Biosciences / Janssen |
| modotuximab | HER1 (ErbB-1) | - | Symphogen |
| mogamulizumab | CCR4 | Poteligeo | BioWa / Kyowa Hakko Kirin Pharma |
| monalizumab | CD94/NKG2A | - | Innate Pharma / AstraZeneca |
| mosunétuzumab | CD20 x CD3e | - | Genentech (Roche) |
| motavizumab | F(protéine de fusion) | Numax | MedImmune (AstraZeneca) |
| moxétumomab pasudotox | CD22 | Lumoxiti | AstraZeneca / Innate Pharma |
| muromonab | CD3ε | Orthoclone OKT3 | Janssen-Cilag |
| naptumomab estéfénatox | 5T4°°°°° | - | Active Biotech |
| natalizumab | α4β1(VLA-4$) | Tysabri | Biogen / Élan |
| nécitumumab | EGFR | Portrazza | Eli Lilly & Company |
| niversimab | F(protéine de fusion) | - | MedImmune (AstraZeneca)Sanofi Pasteur |
| nivolumab | PD-1 | Opdivo | Medarex / Bristol-Myers Squibb |
| obiltoxaximab | PA# exotoxine(Anthrax) | Anthim | Elusys Therapeutics |
| obinutuzumab | CD20 | Gazyvaro / Gazyva | Glycart Biotechnology (Roche) |
| ocrélizumab | CD20 | Ocrevus | Roche |
| ofatumumab | CD20 | Arzerra | Genmab / GlaxoSmithKline |
| omalizumab | IgE | Xolair | Novartis |
| oportuzumab monatox | EpCAM | Vicinium | Viventia Bio |
| otélixizumab | CD3 | - | Tolerx / GlaxoSmithKline |
| otilimab | GM-CSF | - | Morphosys / GlaxoSmithKline |
| oxélumab | Ox40L (CD223) | - | Genentech (Roche) |
| pagibaximab | Acide lipotéichoïque$$$ | - | Biosynexus |
| palivizumab | VRS+++ | Synagis | MedImmune (AstraZeneca) |
| panitumumab | EGFR | ||
| patéclizumab | Lymphotoxine-α | - | Genentech (Roche) |
| pembrolizumab | PD-1 | Keytruda | Merck Sharp and Dohme |
| pertuzumab | HER2/neu | Perjeta | Genentech (Roche) |
| pexélizumab | C5 | - | Alexion Pharmaceuticals |
| pidilizumab | PD-1 (CD279) | - | Medivation |
| polatuzumab védotine-piqq | CD79b | Polivy | Genentech (Roche) |
| porgaviximab | Gp de surface | ZMapp | Mapp Biopharmaceutical / Public Health Agency of Canada |
| prézalizumab | ICOS-L (CD275) | - | Amgen |
| ramucirumab | VEGF-R2 (KDR) | Cyramza | Eli Lilly & Company |
| ranibizumab | VEGF-A | Lucentis | Genentech (Roche) / Novartis |
| ravagalimab | CD40 | - | AbbVie |
| ravulizumab | C5 | Ultomiris | Alexion Pharmaceuticals |
| raxibacumab | PA exotoxine(Anthrax) | ABthrax | Human Genome Sciences / GlaxoSmithKline |
| rélatlimab | LAG-3 (CD223) | - | Bristol-Myers Squibb |
| risankizumab | IL-23Rp19 | - | Boehringer Ingelheim / AbbVie |
| rituximab | CD20 | Rituxan/Mabthera | Genentech (Roche) |
| rolédumab | Rhésus D | - | LFB° Group |
| rontalizumab | IFN-α | - | Genentech / Chugai Pharmaceuticals |
| rovalpituzumab tésirine | DLL3### | Rova-T | Stemcentrx / Abbvie |
| rovélizumab | CD18 | - | Icos Corp. (Eli Lilly & Company) |
| ruplizumab | CD40L (CD154) | Antova | Biogen |
| sacituzumab govitécan | Trop-2 | - | Immunomedics |
| sarilumab | IL-6Rα (CD126) | Kevzara | Regeneron / Sanofi Aventis |
| sécukinumab | IL-17A | Cosentyx | Novartis |
| sélicrélumab | CD40 | - | Roche |
| sévirumab | gH### | - | PDL BioPharma / Novartis |
| sibrotuzumab | Fibroblastactivation protein (FAP) | - | Boehringer Ingelheim Pharma |
| sintilimab | PD-1 (CD279) | Tyvit | Innovent Biologics / Eli Lilly and Co |
| spartalizumab | PD-1 (CD279) | - | Novartis |
| suptavumab | F(protéine de fusion) | - | Regeneron Pharmaceuticals |
| suvratoxumab | Staphylococcus aureus alpha toxin | - | MedImmune (AstraZeneca) |
| tavolimab | OX-40 (CD134) | - | MedImmune (AstraZeneca) |
| téfibazumab | ClfA#### | Aurexis | Inhibitex (Bristol-Myers Squibb) |
| ténéliximab | CD40 | - | ? |
| téplizumab | CD3 | - | ProventionBio |
| théralizumab | CD28 | - | TeGenero Immuno Therapeutics / TheraMAB |
| tigatuzumab | TRAIL-R2(DR5, APO-2) | - | Daiichi Sankyo |
| tiragolumab | TIGIT | - | Genentech (Roche) |
| tislélizumab | PD-1 (CD279) | - | Beigene / Celgene (Bristol-Myers Squibb) |
| tocilizumab | IL-6Rα (CD126) | Actemra/RoActemra | Chugai (Roche) |
| toralizumab | CD40L (CD154) | - | Idec Pharmaceuticals |
| toripalimab | PD-1 (CD279) | - | Shanghai Junshi Bioscience Co |
| tositumomab | CD20 | Bexxar | GlaxoSmithKline |
| trastuzumab | HER2/neu | Herceptine | Genentech / Roche |
| trastuzumab déruxtécan | HER2/neu | - | Daiichi Sankyo |
| trastuzumab duocarmazine | HER2/neu | - | Synthon Biopharmaceuticals BV |
| trémélimumab | CTLA-4 (CD152) | - | Pfizer / Medimmune LLCAstraZeneca |
| ublituximab | CD20 | - | LFB° Group / TG Therapeutics |
| urélumab | 4-1BB (CD137) | - | Bristol-Myers Squibb |
| ustékinumab | IL-23Rp40 | Stelara | Janssen |
| utomilumab | 4-1BB (CD137) | - | Pfizer |
| vanalimab | CD40 | - | Alligator BioScience /Janssen Biotech |
| varlilumab | CD27 | - | Celldex therapeutics |
| védolizumab | α4β7 | Entyvio | Takeda |
| veltuzumab | CD20 | - | Immunomedics |
| volociximab | α5β1 | - | PDL BioPharma / Biogen Idec |
| vopratélimab | ICOS (CD278) | - | Jounce Therapeutics |
++++
anticorps bispécifique anti-protéines sécrétrices de type III (PcrV) et anti-exopolysaccharide (PsI) de la paroi de Pseudomonas aeruginosa
####
Épitope de fixation à la fibrine du facteur d’agglutination A (ClfA) de la paroi de Staphylococcus aureus
§§
Cocktail de deux AcM dirigés contre les sites antigéniques des glycoprotéines I (pour CR57) et III (pour CR4098) de l’enveloppe du virus de la rage (RV, rhabdovirus de la rage)
© 2019 médecine/sciences – Inserm
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.